Quantitative and Systems Pharmacology Workshop II

Sandra RB Allerheiligen

Merck Research Laboratories

Model-based drug development: the road to quantitative pharmacology.

J Pharmacokinet Pharmacodyn. 2006 Jun;33 (3):369-93.

Next-generation model-based drug discovery and development: quantitative and systems pharmacology.

Clin Pharmacol Ther. 2010 Jul;88(1):135-7.

ASCPT Task Force for advancing pharmacometrics and integration into drug development.

Clin Pharmacol Ther. 2010 Aug;88(2):158-61.

Fostering Culture and Optimizing Organizational Structure for Implementing Model-Based Drug Development.

J Clinical Pharmacology (in press 2010)

Pharmacometrics: a multidisciplinary field to facilitate critical thinking in

drug development and translational research settings.

J Clin Pharmacol. 2008 May;48(5):632-49.

Pharmacometrics and the transition to model-based development.

Clin Pharmacol Ther. 2007 Aug;82(2):137-42.

Concepts and challenges in quantitative pharmacology and model-based drug development.

AAPS J.2008 Dec;10(4):552-9.

Russ Altman

Stanford University

Generating genome-scale candidate gene lists for pharmacogenomics.

Clin Pharmacol Ther. 2009 Aug;86(2):183-9.

Improving the prediction of pharmacogenes using text-derived drug-gene relationships.

Pac Symp Biocomput. 2010:305-14.

Andrea Califano

Columbia University

The transcriptional network for mesenchymal transformation of brain tumours.

Nature. 2010 Jan 21;463(7279):318-25.

Towards patient-based cancer therapeutics, The Cancer Target Discovery and Development Network, Nature Biotechnology, in press

A human B-cell interactome identifies MYB and FOXM1 as master regulators

of proliferation in germinal centers

Molecular Systems Biology 6, (8 June 2010)

Genome-wide identification of post-translational modulators of transcription factor activity in human B cells.

Nat Biotechnol. 2009 Sep;27(9):829-39.

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Nature. 2009 Jun 4;459(7247):717-21

A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas.

Mol Syst Biol. 2008;4:169.

Jenny Chien

Eli Lilly and Company

The Application of Drug-Disease Models in the Development of Anti-hyperglycemic Agents.

Chapter 9 in “Clinical Trial Simulations:

Applications and Trends” ed. H Kimko and P Carl, Springer Science

+ Business Media, 2010. (in press)

An integrated model for the glucose-insulin system.

Basic Clin Pharmacol Toxicol. 2010 Mar;10 (3):189-94..

A model for glucose, insulin, and Beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.

J Clin Pharmacol. 2010 Aug;50(8):861-72..

Mathematical models of diabetes progression.

Am J Physiol Endocrinol Metab. 2008 Dec;295 (6):E1462-79.

David D’Argenio

University of Southern California

Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning.

Bioinformatics. 2010 Mar 15;26(6):807-13.

Population Pharmacokinetic/Pharmacodyanamic Mixture Models via Maximum

a Posteriori Estimation.

Comput Stat Data Anal. 2009 Oct 1;53(12):3907- 3915.

Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Clin Pharmacokinet. 2008;47(7):417-48.

Kathleen M. Giacomini

University of California San Francisco

Membrane transporters in drug development.

Nat Rev Drug Discov. 2010 Mar;9(3):215-36.

Comparison of human solute carriers.

Protein Sci. 2010 Mar;19(3):412-28.

Nathanael Gray

Dana-Farber Cancer Institute/ Harvard University

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Nature. 2010 Jan 28;463(7280):501-6.

Richard Lalonde

Pfizer Inc

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.

J Clin Pharmacol. 2009 Nov;49(11):1297-308.

Donald E. Mager

University of Buffalo

Development of translational pharmacokinetic-pharmacodynamic models.

Clin Pharmacol Ther. 2008 Jun; 83(6):909-12.

Timothy J. Mitchison

Harvard Medical School

Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.

Cancer Cell. 2009 Oct 6;16(4):347-58

Brian Shoichet

University of California, San Francisco

Relating protein pharmacology by ligand chemistry.

Nat Biotechnol. 2007 Feb; 25(2):197-206.

Predicting new molecular targets for known drugs.

Nature. 2009 Nov 12; 462(7270):175-81.

Peter Sorger

Harvard Medical School

Non-genetic cell-to-cell variability and the consequences for pharmacology.

Curr Opin Chem Biol. 2009 Dec; 13(5-6):556-61

Networks inferred from biochemical data reveal profound differences in TLR and inflammatory signaling between normal and transformed hepatocytes.

Mol Cell Proteomics. 2010 May 10.

Dissecting variability in responses to cancer chemotherapy through systems pharmacology.

Clin Pharmacol Ther. 2010 Jul;88(1):34-8

Shankar Subramaniam

University of California San Diego

Mechanisms of human insulin resistance and thiazolidinedione-mediated

insulin sensitization.

Proc Natl Acad Sci U S A. 2009 Nov 3;106 (44):18745-50.

Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.

J Clin Invest. 2007 Jun; 117(6):1658-69.

Bivariate microarray analysis: statistical interpretation of two-channel functional genomics data.

Syst Synth Biol. 2008 Dec;2(3-4):95-104.

Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes.

Bioinformatics. 2004 Nov 22;20(17):3108-27.

Piet Van der Graaf

Pfizer Global Research and Development

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

Drug Discov Today. 2007 Dec; 12(23-24):1018-24

Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.

Antimicrob Agents Chemother. 2010 Mar; 54(3):1179-85.

Impact of plasma-protein binding on receptor occupancy: an analytical description.

J Theor Biol. 2009 Jan 21;256(2):253-62.

Pharmacokinetic–pharmacodynamic reasoning in drug discovery and early development

Future Medicinal Chemistry, Nov 2009, Vol. 1, No. 8, Pages 1371-1374.

Yaning Wang, Ph.D.

Food and Drug Administration

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.

Clin Pharmacol Ther. 2009 Aug;86(2):167-74.

Quantitative disease, drug, and trial models.

Annu Rev Pharmacol Toxicol. 2009;49:291-301.

Lani Wu

University of Texas Southwestern Medical Center at Dallas

Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.

Mol Syst Biol. 2010 May 11;6:369.

Heterogeneity in the physiological states and pharmacological responses of differentiating 3T3-L1 preadipocytes.

J Cell Biol. 2009 Nov 2; 187(3):375-84.

Speaker References